NCT07740642Not yet recruiting
A Comparative Usability Study of Two Total Body Skin Imaging Systems
Summary
This study aims to generate evidence on patient and dermatologist perspectives regarding two total body photography systems. Patient and clinician preferences represent key factors in healthcare decision-making. The investigation will also provide data on the time efficiency of each system in a real-world setting.
Inclusion criteria
• Age ≥ 18 years • Signed informed consent by the participant • Sufficient proficiency in German • At least one of the following risk criteria for melanoma: • Previous melanoma (including in situ) • Suspected melanoma • ≥ 100 common naevi • ≥ 5 dysplastic naevi • dysplastic naevus syndrome • Known CDKN2A mutation • Strong family history for melanoma (≥ first- and/or second-degree relatives)
Exclusion criteria
• Lack of informed consent • Immobility. (Patients must be able to stand without support for 30 minutes.) • Inability to follow the procedures of the investigation, including inability to follow on-screen instructions or to read (e.g. due to visual impairment or cognitive impairment) • Vulnerable Subjects • Active skin conditions that may impact the performance of TBP systems or skin cancer screenings • Cardiac pacemaker • Pregnant women (self reported, no pregnancy test planned) • Height below 150 cm or above 195 cm • Severe Claustrophobia
Contacts
The trial team's contact details are shown on request.
See the official trial record- Status
- Not yet recruiting
- Phase
- No phase (N/A)
- Study type
- Interventional
- Countries
- Switzerland
- Sponsor
- University Hospital, Basel, Switzerland(Other)
- Protocol no.
- 2026-D0060; th26navarini
- Conditions
- Melanoma (Skin Cancer)
- Interventions
- Device, Other
Treatments studied
- Deviskan
- Vectra WB360
- Standard-of-care clinical examinations
Locations · 1
- Basel, SwitzerlandUniversity Hospital BaselNot yet recruiting at this site
In total, worldwide, the only site listed in the registry is planned; recruitment has not opened yet.
Site status per the ClinicalTrials.gov registry (last update posted: August 3, 2026).
This status may have changed and says nothing about your eligibility: before taking any step, check with your oncologist or the site.
See also
Other versions
These results are indicative and do not replace medical advice — discuss them with your doctor.